• otv
Nitesh Kumar Sahoo

News Highlights

  • Bharat Biotech International Ltd on Monday announced quick ramping up of its additional manufacturing capacities for its Indigenous COVID-19 vaccine- Covaxin at CHIRON BHRING Vaccines, a wholly owned subsidiary of Bharat Biotech, in Ankleshwar, Gujarat.

Bhubaneswar: Hyderabad-based Bharat Biotech International Ltd on Monday announced quick ramping up of its additional manufacturing capacities for its Indigenous COVID-19 vaccine- Covaxin at CHIRON BEHRING Vaccines, a wholly owned subsidiary of Bharat Biotech, in Ankleshwar, Gujarat.

The vaccine manufacturing company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety. 

The product availability at the subsidiary in Gujarat will commence from Q4 2021. 

Bharat Biotech had already deployed multiple production lines at its Hyderabad and Bengaluru campuses. Adding Chiron Behring to this line of high containment BSL rated GMP facilities that are required to manufacture Covaxin. This will scale up the volume of vaccine manufacturing to 1 billion doses per annum. 

Its own established campuses are specialized for manufacturing inactivated viral vaccines under the highest level of biosafety, said the company in a release.
 

Other Stories